FDA Bars Tyler Jordan Hall from Drug Imports After Conviction
Published Date: 1/23/2026
Notice
Summary
Tyler Jordan Hall is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of bringing in unapproved drugs. He didn’t respond to the FDA’s notice, so the ban starts January 23, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping the market safer and cleaner!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Five-Year Import Ban on Named Importer
The FDA debarred Tyler Jordan Hall for 5 years, effective January 23, 2026, prohibiting him from importing or offering for import any drug into the United States. The order also makes importing any drug by, with the assistance of, or at the direction of Mr. Hall a prohibited act.
Right to Apply to End Debarment Anytime
Mr. Hall may apply at any time to terminate his debarment under section 306(d)(1) of the FD&C Act. Applications may be submitted electronically at https://www.regulations.gov (Docket No. FDA-2025-N-1331) or as written/paper submissions to the Dockets Management Staff with options to mark confidential information as described in the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-01295 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Regional Economic Development Data Collection Instrument
The Department of Commerce wants your thoughts on a new survey that helps track how regions grow their economies. This affects communities and businesses that work with the Economic Development Administration, and your feedback is needed by March 24, 2026. The goal is to keep the survey helpful but easy to fill out, with no extra costs for participants.
Next: 2026-01297 — Application for Authorization To Export Electric Energy; Electric Power Markets USA, LLC
Electric Power Markets USA, LLC wants permission to send electricity from the U.S. to Mexico for the next five years. This affects energy buyers and sellers in Texas and could boost cross-border power trade without hurting U.S. electricity supplies. If you have thoughts or concerns, you’ve got until February 23, 2026, to speak up!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in